Ultragenyx Pharmaceutical (RARE) Revenue: 2016-2025
Historic Revenue for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $159.9 million.
- Ultragenyx Pharmaceutical's Revenue rose 14.65% to $159.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.6 million, marking a year-over-year increase of 20.63%. This contributed to the annual value of $560.2 million for FY2024, which is 29.01% up from last year.
- Ultragenyx Pharmaceutical's Revenue amounted to $159.9 million in Q3 2025, which was down 3.94% from $166.5 million recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's Revenue registered a high of $166.5 million during Q2 2025, and its lowest value of $79.9 million during Q1 2022.
- Its 3-year average for Revenue is $132.7 million, with a median of $139.3 million in 2025.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's Revenue spiked by 173.75% in 2021 and then fell by 19.58% in 2022.
- Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Revenue stood at $83.4 million in 2021, then increased by 23.93% to $103.3 million in 2022, then rose by 23.27% to $127.4 million in 2023, then increased by 29.42% to $164.9 million in 2024, then rose by 14.65% to $159.9 million in 2025.
- Its last three reported values are $159.9 million in Q3 2025, $166.5 million for Q2 2025, and $139.3 million during Q1 2025.